West Pharmaceutical Beats Q3 Estimates, Raises FY2026 Outlook on Strong HVP Demand

What happened

West Pharmaceutical Services reported third-quarter results that exceeded its own expectations, driven by continued demand for high-value product components used in GLP-1 therapies and biologics. This follows a strong Q2 where organic sales grew 12.7% and the company raised its full-year guidance. The Q3 beat and subsequent raise of full-year revenue and adjusted earnings outlook indicate that the HVP-led growth momentum continued through the third quarter. The company now expects higher revenue and EPS than previously guided, which aligns with the master report's base case of steady HVP growth. However, valuation remains demanding at 42.9x P/E and 32.7x EV/EBITDA, meaning the market continues to price in sustained growth and successful capacity conversion.

Implication

The Q3 earnings beat and full-year guidance raise indicate that West's high-value product mix continues to translate into financial outperformance, supporting the view that the company's moat in injectable components remains intact. However, at 42.9x forward earnings and 32.7x EV/EBITDA, the stock already reflects expectations for continued double-digit organic growth and successful absorption of new capacity, leaving little room for error. Investors should focus on whether the raised guidance is still conservative and whether gross margins can hold at or above the Q2 level of 37.7%, as any slip could trigger a multiple de-rating. The key risk remains a potential shift toward oral GLP-1 formats or less frequent dosing, which would disproportionately affect West's high-margin component volumes, and the market has not yet priced in such a scenario. As such, the prudent approach is to hold current positions but wait for a pullback toward the $300 area or further evidence of Dublin revenue contribution before adding, consistent with the master report's WAIT rating.

Thesis delta

The Q3 beat and raise slightly reinforce the operating momentum highlighted in the master report, confirming that HVP demand remains durable. However, the premium valuation was already predicated on such outcomes, so the investment thesis remains a WAIT; the stock offers adequate risk/reward only below $300 or after further evidence of margin durability beyond the next two quarters.